Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb

British Journal of Cancer
A W HitchingsD M Berney

Abstract

Currently available prognostic tools appear unable to adequately predict recurrence and progression in non muscle-invasive bladder carcinomas. We aimed to assess the prognostic value of immunohistochemical evaluation of the cell cycle markers p53, p16 and pRb. Paraffin blocks were obtained from 78 cases of pTa and pT1 transitional cell carcinomas, for which long-term follow-up was available. Representative sections were stained using antibodies against p53, p16 and pRb. Altered marker expression was found in 45, 17 and 30% of cases, respectively. Concurrent alteration of two or three markers occurred in 19% of cases, and was significantly associated with grade and stage. In univariate survival analysis, the concurrent alteration of any two markers was significantly associated with progression. The greatest risk was produced by alteration of both p53 and p16, which increased the risk of progression by 14.45 times (95% confidence interval (CI) 3.10-67.35). After adjusting for grade and stage, this risk was 7.73 (CI 1.13-52.70). The markers did not generally predict tumour recurrence, except in the 25 pT1 tumours. In these, p16 alteration was associated with a univariate risk of 2.83 (CI 1.01-7.91), and concurrent p53 and p16 alte...Continue Reading

References

Jan 1, 1973·International Urology and Nephrology·W Vahlensieck, L Weissbach
Feb 1, 1994·International Journal of Cancer. Journal International Du Cancer·C Cordon-CardoA Pellicer
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L LacombeV E Reuter
Jul 8, 1999·The American Journal of Pathology·I OrlowC Cordon-Cardo
Jul 31, 2001·Molecular Pathology : MP·M A Knowles
Oct 10, 2002·Urologia Internationalis·Ching-Chiang YangWen-Chi Chen
Feb 1, 2003·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·L L SantosC S Lopes
Feb 8, 2003·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Pavel Rohan, Stanislav Komenda
Apr 15, 2003·The Journal of Pathology·John R W MastersUNKNOWN MRC Superficial Bladder Cancer Group Mitomycin-C Trial Collaborators

❮ Previous
Next ❯

Citations

Mar 13, 2008·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Andrea BrunnerAlexandar Tzankov
Aug 22, 2007·World Journal of Urology·Anirban P MitraRichard J Cote
Oct 23, 2009·American Journal of Clinical Pathology·Kumiko NakazawaRyohei Katoh
Mar 29, 2006·BJU International·Harry W Herr, S Machele Donat
Feb 19, 2010·International Journal of Surgical Pathology·Natalia BuzaVinita Parkash
Apr 1, 2005·International Journal of Cancer. Journal International Du Cancer·Iman J SchultzJacques B de Kok
Oct 5, 2010·Journal of Korean Medical Science·Kyungji LeeAhwon Lee
Oct 26, 2006·World Journal of Urology·Christopher Y Thomas, Dan Theodorescu
Sep 17, 2014·The Kaohsiung Journal of Medical Sciences·Ching-Hsiu YangSheau-Fang Yang
Oct 2, 2009·BJU International·Richard T BryanKar Keung Cheng
Jun 29, 2010·Histopathology·Ian ProctorGareth H Williams
Jul 27, 2005·Journal of Lower Genital Tract Disease·Peter A DrewDaylene L Ripley
Jan 23, 2008·American Journal of Clinical Pathology·Samia GonzalezXavier Leroy
Feb 23, 2011·Der Urologe. Ausg. A·M Burger, F Vom Dorp

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.